Rockwell Medical, Inc. (RMTI) vs TherapeuticsMD, Inc. (TXMD)

Rockwell Medical, Inc. and TherapeuticsMD, Inc. are both Drug Manufacturers Specialty & Generic companies. Rockwell Medical, Inc. is the larger, with a market value of $34.5M against $24.7M — 1.4× the size. TherapeuticsMD, Inc. grew revenue faster over the last twelve months: 27.8% against −21.1%. TherapeuticsMD, Inc. has the higher net margin (−6.64% vs −7.33%) and the higher return on invested capital (−13.8% vs −14.6%). Across the 18 metrics below, TherapeuticsMD, Inc. leads on 13 and Rockwell Medical, Inc. on 5.

Valuation

Metric RMTI TXMD Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 0.48 7.26 2.25
P/B 0.95 0.87 1.90
Price to free cash flow n/m 8.72 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 0.25 6.95 2.56
Earnings yield (15.95%) (1.14%) (2.99%)
Free cash flow yield (2.95%) 11.47% 0.00%

Profitability

Metric RMTI TXMD Drug Manufacturers Specialty & Generic median
Gross margin 17.71% 100.00% 53.94%
Operating margin (6.52%) (120.89%) 0.00%
Net margin (7.33%) (6.64%) 0.00%
Free cash flow margin 2.47% 94.71% 0.00%
Return on equity (15.53%) (0.80%) (0.40%)
Return on assets (9.32%) (0.57%) (3.32%)
Return on invested capital (14.58%) (13.77%) 0.00%

Growth

Metric RMTI TXMD Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (21.12%) 27.78% 10.01%
EPS growth (last fiscal year) (870.87%) 73.68% —
Revenue growth, 5-year CAGR 2.17% (45.84%) 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric RMTI TXMD Drug Manufacturers Specialty & Generic median
Debt to equity 0.26 0.00 0.05
Current ratio 3.25 3.22 2.31
Net debt to EBITDA 7.40 2.34 0.85

Dividend

Metric RMTI TXMD Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric RMTI TXMD Drug Manufacturers Specialty & Generic median
Market cap 34.54m 24.65m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack